Literature DB >> 26619409

Prevalence and Characteristics of Human Metapneumovirus Infection Among Hospitalized Children at High Risk for Severe Lower Respiratory Tract Infection.

Evan J Anderson1, Eric A F Simões2, Jim P Buttery3, Penelope H Dennehy4, Joseph B Domachowske5, Kathryn Jensen6, Jay M Lieberman7, Genevieve A Losonsky6, Ram Yogev1.   

Abstract

BACKGROUND: Human metapneumovirus (HMPV) is a significant cause of respiratory tract infections. Little is known about HMPV in children who are at high risk for lower respiratory tract infection (LRTI).
METHODS: To determine the prevalence of HMPV in high-risk children and to identify HMPV risk factors, children ≤24 months with prematurity, chronic lung disease, and/or congenital cardiac disease who were hospitalized with LRTI were prospectively enrolled. Nasopharyngeal aspirates were tested for HMPV, respiratory syncytial virus (RSV), influenza A and B, and parainfluenza types 1-3. Demographics, medical history, and outcomes for those with HMPV and RSV were compared. A multivariate analysis was performed to determine HMPV risk factors.
RESULTS: Over 4 years, 1126 eligible children were enrolled. Pathogens were identified in 61% of subjects. HMPV was identified in 9.0%, second to RSV (45%). Coinfection with HMPV and RSV occurred in <1% of subjects. Subjects infected with HMPV were older (8.2 vs 4.0 months, P < .001), were born more prematurely (27 vs 33 weeks, P < .001), and more commonly had chronic lung disease (59.3% vs 21.8%, P < .001) compared with subjects infected with RSV. In a multivariate analysis that compared children infected with HMPV to all others, increasing age and household exposure to children ages 6-12 were associated with an increased risk, whereas birth at older gestational age and exposure to children age >12 were associated with a decreased risk.
CONCLUSIONS: HMPV was detected in 9% of high-risk children who were hospitalized with lower respiratory tract disease, representing the second most common virus in this population. Compared with all other subjects (including RSV-infected), subjects infected with HMPV were older but were born more prematurely.
© The Author 2012. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Year:  2012        PMID: 26619409     DOI: 10.1093/jpids/pis069

Source DB:  PubMed          Journal:  J Pediatric Infect Dis Soc        ISSN: 2048-7193            Impact factor:   3.164


  15 in total

1.  Clinical Features of Human Metapneumovirus-Associated Community-acquired Pneumonia Hospitalizations.

Authors:  Leigh M Howard; Kathryn M Edwards; Yuwei Zhu; Carlos G Grijalva; Wesley H Self; Seema Jain; Krow Ampofo; Andrew T Pavia; Sandra R Arnold; Jonathan A McCullers; Evan J Anderson; Richard G Wunderink; Derek J Williams
Journal:  Clin Infect Dis       Date:  2021-01-23       Impact factor: 9.079

2.  Burden of human metapneumovirus infection in young children.

Authors:  Kathryn M Edwards; Yuwei Zhu; Marie R Griffin; Geoffrey A Weinberg; Caroline B Hall; Peter G Szilagyi; Mary A Staat; Marika Iwane; Mila M Prill; John V Williams
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

3.  Human metapneumovirus in the preterm neonate: current perspectives.

Authors:  Nathalie L Maitre; John V Williams
Journal:  Res Rep Neonatol       Date:  2016-07-28

4.  Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis.

Authors:  Evan J Anderson; Phyllis Carosone-Link; Ram Yogev; Jumi Yi; Eric A F Simões
Journal:  Pediatr Infect Dis J       Date:  2017-08       Impact factor: 2.129

5.  Human metapnuemovirus infections in hospitalized children and comparison with other respiratory viruses. 2005-2014 prospective study.

Authors:  María Luz García-García; Cristina Calvo; Cristina Rey; Beatriz Díaz; Maria Del Mar Molinero; Francisco Pozo; Inmaculada Casas
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

6.  Comparing Human Metapneumovirus and Respiratory Syncytial Virus: Viral Co-Detections, Genotypes and Risk Factors for Severe Disease.

Authors:  Nina Moe; Sidsel Krokstad; Inger Heimdal Stenseng; Andreas Christensen; Lars Høsøien Skanke; Kari Ravndal Risnes; Svein Arne Nordbø; Henrik Døllner
Journal:  PLoS One       Date:  2017-01-17       Impact factor: 3.240

7.  Clinical Features of Human Metapneumovirus Infection in Ambulatory Children Aged 5-13 Years.

Authors:  Leigh M Howard; Kathryn M Edwards; Yuwei Zhu; Marie R Griffin; Geoffrey A Weinberg; Peter G Szilagyi; Mary A Staat; Daniel C Payne; John V Williams
Journal:  J Pediatric Infect Dis Soc       Date:  2018-05-15       Impact factor: 3.164

Review 8.  Prophylactic and therapeutic approaches for human metapneumovirus.

Authors:  Prashant Kumar; Mansi Srivastava
Journal:  Virusdisease       Date:  2018-10-20

Review 9.  Interferon-Mediated Response to Human Metapneumovirus Infection.

Authors:  Ifeanyi K Uche; Antonieta Guerrero-Plata
Journal:  Viruses       Date:  2018-09-18       Impact factor: 5.048

Review 10.  Human metapneumovirus - what we know now.

Authors:  Nazly Shafagati; John Williams
Journal:  F1000Res       Date:  2018-02-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.